BiotechTube

Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)

ApprovedCompleted
3 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

COVID-19

Conditions

COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease

Trial Timeline

Nov 22, 2023 → Sep 9, 2024

NCT ID
NCT06065176

About Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)

Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) is a approved stage product being developed by Novavax for COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT06065176. Target conditions include COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection.

What happened to similar drugs?

6 of 20 similar drugs in COVID-19 were approved

Approved (6) Terminated (4) Active (12)
✅mRNA-1283.251 Variant-containing FormulationModernaApproved
✅AZD1222AstraZenecaApproved
✅AZD1222AstraZenecaApproved
✅Rivaroxaban 10 mgBayerApproved
✅protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineNovavaxApproved
✅NVX-CoV2705 + PlaceboNovavaxApproved
🔄mRNA-1283.222ModernaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06065176ApprovedCompleted

Competing Products

20 competing products in COVID-19

See all competitors
ProductCompanyStageHype Score
mRNA-1283.251 Variant-containing FormulationModernaApproved
0
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
InfliximabCelltrionPhase 2
35
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
32
Enzalutamide PillAstellas PharmaPhase 2
27
S-892216 + PlaceboShionogiPhase 2
35
S-892216 + CarbamazepineShionogiPhase 1
29
FOY-305 + PlaceboOno PharmaceuticalPhase 3
40
DesidustatZydus LifesciencesPhase 2
35
LY3819253 + PlaceboEli LillyPhase 1
29